Cure My Disease

Don't miss your cure!

 Log in / Sign up

OMNIPHYS: a prospective multimodal longitudinal study of AI-Enabled physiologic state modeling and early detection of clinical deterioration

NCT ID NCT07814118

NEW Sponsor: Truway Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 10, 2026

Summary

The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state over time. The study will examine cardiac, vascular, pulmonary, and systemic physiologic measurements and develop longitudinal models that describe baseline physiology, physiologic perturbation, compensation, deterioration, treatment response, and recovery. The study is observational and will not assign experimental treatments. The goal is to determine whether changes in multimodal physiologic patterns can be identified and characterized earlier and more reliably than conventional single-time-point assessment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Sep 2046

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

OMNIPHYS will enroll a diverse adult population including healthy volunteers and participants receiving routine clinical evaluation or care. The study will include individuals across cardiovascular, vascular, pulmonary, renal, and systemic physiologic conditions, with disease-specific and physiologic subcohorts analyzed within a common longitudinal framework. Multimodal ultrasound, Doppler, physiologic measurements, clinical data, laboratory data, and longitudinal outcomes will be evaluated to characterize individual physiologic states, trajectories, transitions, treatment responses, and recovery patterns.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or older who are capable of providing informed consent, or who meet applicable legally authorized representative requirements where permitted. 2. Individuals undergoing routine clinical evaluation, diagnostic imaging, monitoring, treatment, or longitudinal follow-up, including individuals with relevant cardiovascular, vascular, pulmonary, renal, systemic, or other conditions represented within the OMNIPHYS research framework. 3. Healthy volunteers without the conditions under study may participate as reference participants. 4. Ability to undergo at least one protocol-relevant physiologic or imaging assessment and/or contribute eligible routinely collected clinical data. 5. Availability of sufficient clinical, physiologic, imaging, or longitudinal outcome data for the applicable analysis. 6. Willingness to permit collection and longitudinal analysis of protocol-defined research data in accordance with informed consent and applicable privacy and data-governance requirements. Exclusion Criteria: 1. Inability or unwillingness to provide informed consent or otherwise meet applicable consent requirements. 2. Inability to obtain interpretable protocol-relevant physiologic or imaging data when such data are required for the applicable analysis. 3. Conditions or circumstances that, in the judgment of the responsible clinical investigator, make participation inappropriate or prevent meaningful longitudinal follow-up. 4. Withdrawal of consent or request for discontinuation of research participation where applicable. 5. Any circumstance that would prevent collection, secure handling, or analysis of study data in accordance with the approved protocol and applicable requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury acute myocarditis acute respiratory distress syndrome adult acute respiratory distress syndrome aortic disorder brain aneurysm cardiomyopathy Clinical Deterioration disease heart failure heart valve disorder hypertensive disorder infectious disease with sepsis musculoskeletal system disorder myocarditis peripheral arterial disease pulmonary edema pulmonary embolism pulmonary hypertension Sepsis thrombophilia due to thrombin defect toxic myocarditis Venous Thrombosis viral myocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Acute respiratory distress syndrome Aortic diseases Brain aging Brain aging related conditions Brain aneurysm Cardiomyopathies Heart failure Hypertension Muskuloskeletal diseases Myocarditis due to drug Myocarditis viral Myocarditis; acute or subacute Pericardial diseases Peripheral arterial disease Peripheral arterial disease(PAD) Pulmonary edema - acute Pulmonary edema with heart failure Pulmonary edemas Pulmonary embolism (diagnosis) Pulmonary embolism acute Pulmonary embolism acute massive Pulmonary embolism subacute massive Pulmonary hypertension Sepsis Ultrasound Ultrasound exams Ultrasound guidance Valvular heart diseases Venous thrombosis (disorder) Venous thrombosis pulmonary Venous thrombosis, deep

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Truway Health, Inc.

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.